ReviewJournal of medicinal chemistry2024
Unnatural Amino Acids: Strategies, Designs, and Applications in Medicinal Chemistry and Drug Discovery.
Review in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Application and progress of synthetic biology technology in amino acid production.Bioprocess and biosystems engineering · 2026Review
- Immobilized Wild-Type and Mutant L‑Alanine Dehydrogenase fromACS omega · 2026Article
- HighFold4: extending AlphaFold3 to accurate cyclic peptide conformation prediction via custom chemical connectivity.Briefings in bioinformatics · 2026Article
- Azole γ-Peptides Helix Switching via Heterocycle Substitutions.Angewandte Chemie (International ed. in English) · 2026Article
- A pyridoxal phosphate-dependent enzyme platform for stereoselective synthesis of γ-tertiary-nitro-noncanonical amino acids.Nature communications · 2026Article
- Synthesis and Characterization of New Functionalized Pyrimidine (Hetero)Cyclic Molecular Hybrids as Chiral Heterocyclic Amino Acid Derivatives.Molecules (Basel, Switzerland) · 2026Article
- Bridging stimulus-responsive and dissipative peptide assemblies to build complex interactive biomaterials.Nature reviews. Chemistry · 2026Review
- Direct Stereospecific Deoxyamination of Alcohols Enabled by Li-Mediated SuFEx.Organic letters · 2026Article
- Catalytically Promiscuous PLP-Dependent Aminotransferases Are Biocatalysts for C-C Bond Formation.ACS central science · 2026Article
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.Antibody therapeutics · 2026Review
- Peptide-Based pH-Responsive MRI-CEST Agents: In Vivo Comparison between a Selected Pentapeptide and the Established Iopamidol Reference in Tumor pH Mapping Ability.Chemical & biomedical imaging · 2026Article
- Unnatural amino acid compounds as potent multi-target inhibitors of aldose reductase, α-glucosidase, and α-amylase: integrated in vitro, SAR, and molecular dynamics insights.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Direct Access to Iron Carbenes from Aldehyde, Ketone, and Formamide Feedstocks.Journal of the American Chemical Society · 2026Article
- Beyond the Single Molecule: Multiplexed Methods in Force Spectroscopy.Annual review of biophysics · 2026Review
- Transfer RNA deacylases as beacons for non-canonical amino acid biosynthesis.Nature chemistry · 2026Article
- A Versatile Strategy for Head-to-Tail Macrocyclization and Traceless Backbone Editing of Short Peptides.Journal of the American Chemical Society · 2026Article
- Article
- Expedient Synthesis ofJournal of the American Chemical Society · 2026Article
- Design of Phosphine-Heteroarenesulfonamide Ligands as Dinuclear Silver Catalysts for Enantioselective Construction of α,β-Diamino Acids.Journal of the American Chemical Society · 2026Article
- Chiral cyclopropenimine-catalyzed enantioselective Michael reactions of phenol and benzofuran-derived α,β-unsaturated pyrazolamides with benzophenone-imine of glycine esters.Beilstein journal of organic chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Peptides can operate as therapeutic agents that sit within a privileged space between small molecules and larger biologics. Despite examples of their potential to regulate receptors and modulate disease pathways, the development of peptides with drug-like properties remains a challenge. In the quest to optimize physicochemical parameters and improve target selectivity, unnatural amino acids (UAAs) have emerged as critical tools in peptide- and peptidomimetic-based drugs. The utility of UAAs is illustrated by clinically approved drugs such as methyldopa, baclofen, and gabapentin in addition to small drug molecules, for example, bortezomib and sitagliptin. In this Perspective, we outline the strategy and deployment of UAAs in FDA-approved drugs and their targets. We further describe the modulation of the physicochemical properties in peptides using UAAs. Finally, we elucidate how these improved pharmacological parameters and the role played by UAAs impact the progress of analogs in preclinical stages with an emphasis on the role played by UAAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.